Iovance Biotherapeutics, Inc. IOVA Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$353.86M+5.7% | -$390.98M-5.1% | -$397.63M+3.0% | -$389.92M+11.4% | -$375.36M+16.5% | ||
| $12.93M+9.2% | $12.68M+3.5% | $12.23M+2.5% | $12.25M+3.5% | $11.85M+1.0% | ||
| $49.93M-56.7% | $61.58M-43.8% | $80.74M-13.2% | $99.84M+28.2% | $115.36M+79.9% | ||
| -$270.79M+19.0% | -$302.41M+14.3% | -$323.14M+11.1% | -$303.41M+22.0% | -$334.39M+13.0% | ||
| $34.23M+161% | $33.84M+206% | $28.68M+175% | $20.13M+71.8% | $13.11M-37.0% | ||
| $43.02M— | $47.5M— | —— | —— | —— | ||
| $251.79M-26.0% | $300.77M-23.0% | $246.91M-36.6% | $200.81M-63.5% | $340.4M-14.5% | ||
| —— | —— | —— | —— | $37.43M+109% | ||
| -$305.02M+12.2% | -$336.24M+7.6% | -$351.82M+6.0% | -$323.54M+19.2% | -$347.5M+14.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Iovance Biotherapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.